Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can cleansing the blood reverse frailty? trial tests plasma exchange

NCT ID NCT07836127

Symptom relief Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 23, 2026 · Last updated Sep 24, 2026 · Updated 1 time

Summary

Researchers are testing whether plasma exchange combined with human albumin, with or without intravenous immunoglobulin (IVIG), can improve frailty in older adults. The trial enrolls 34 participants with a FRAIL scale score of 1 or higher and randomly assigns them to one of two treatment groups. Over five months, participants receive six monthly plasma exchange sessions, and researchers track changes in frailty, physical function, and inflammation markers. The goal is to see if this approach is safe and effective for frailty.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Plasma exchange combined with human albumin, with or without intravenous immunoglobulin (IVIG)
What this could lead to
If it works, this approach could offer a new biological treatment for frailty, a condition that currently has few effective options beyond nutrition and exercise.
What could go wrong
This is a small, early-stage trial with only 34 participants, so results may not hold up in larger studies. Plasma exchange is invasive and carries risks like infection, bleeding, and reactions to the replacement fluids.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 34 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years. 2. Clear consciousness and ability to communicate. 3. Sufficient cognitive function and educational level to complete all study-related assessments. 4. A score of ≥ 1 on the FRAIL scale. 5. Voluntary written informed consent. Exclusion Criteria: 1. Known allergy or hypersensitivity to albumin (ALB) or intravenous immunoglobulin (IVIg). 2. Currently receiving albumin (ALB) and/or intravenous immunoglobulin (IVIg) infusion for other reasons. 3. Severe cardiac, hepatic, or renal insufficiency. 4. Active infection or acute exacerbation of chronic infection. 5. Current use of direct oral anticoagulants (DOACs). 6. History of bleeding disorders or coagulation dysfunction. 7. Concomitant malignancy or expected survival of less than 6 months. 8. Severe visual, auditory, or motor function impairment. 9. Refusal to sign the informed consent form. 10. Other conditions that, in the opinion of the investigator, make the participant unsuitable for the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Frailty are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Frailty

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Frailty Plasma exchange

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Institute of Hematology & Blood Diseases Hospital, China

    Tianjin, Tianjin Municipality, 300041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.